

P&T Committee Meeting Minutes

Subject:	Louisiana Department of Health Medicaid Pharmaceutical and Therapeutic Committee Meeting
Location:	628 North Fourth Street Baton Rouge, LA Bienville Building Room 118 And Virtual Zoom Webinar: https://magellanhealth.zoom.us/webinar/register/WN_6KB6Hm2IRBu5FOPvyNuQ6g
Date:	October 27, 2023
Members Present:	▪ Ben Orlando, RPh ▪ Dr. Jill Comeau ▪ Dr. Scott Black ▪ Dr. Julio E. Figueroa ▪ Dr. Mary C. Raven ▪ Ashley M. Volion ▪ Dr. Tammy D. Hart ▪ Senator Fred H. Mills, JR. ▪ Dr. James Hussey
LDH Pharmacy Program Staff Present:	▪ Sue Fontenot, RPh ▪ Melwyn Wendt, PharmD ▪ Haley Williams ▪ Rachel Broussard, RPh ▪ Katrina Johnson ▪ Germaine Becks-Moody (virtually)
Contractors Present:	▪ Hind Douiki, PharmD, Magellan Medicaid Administration ▪ Kara Delaney, PharmD, Magellan Medicaid Administration (virtually) ▪ Kimberly L. Gibney, Certified Court Reporter

Others Present: Presenters are listed in the minutes and sign in sheets and others in attendance from LDH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

Call to Order

Mr. Ben Orlando, Chairman, called the meeting to order at or around 9:04 am. He indicated quorum was not reached. He stated that this meeting will be a review, in which no votes will be made by the P&T committee members. Rather, recommendations can be made by the members and the Secretary will make the final PDL decisions.

Parliamentary Business

- A. Introduction of Members/Roll Call.** Committee members, LDH staff, and contractors introduced themselves.
- B. Approval of Meeting Minutes.** Mr. Orlando indicated members cannot vote to approve the minutes. He asked the members if they have any questions or corrections about the minutes; there were none.

Reports

- A. PDL Reflecting Spring 2023 Recommendations.** Dr. Wendt indicated she has no reports to review.

New Business

- A. Explanation of TOP\$, Monographs and Cost Sheets**

Mr. Orlando indicated there was no need to present this material as there are no new members on the P&T committee. He asked if any member has any questions about TOP\$, Monographs and Cost Sheets; there were no questions.
- B. Therapeutic Class Reviews of Fall Drug Classes/Drug Manufacturer Testimony.** In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
Sharon Hall	Hemophilia Drug Class	Hemophilia Drug Class
Lynda Finch	Biogen	Spinraza
Corey Hicks	Horizon Pharma	Ravicti Oral Liquid

****NOTE:** Names of speakers who were present and yielded their time back were not captured.

Alzheimer's Agents

Recommendations for the PDL are:

- DONEPEZIL ODT (ORAL)
- DONEPEZIL TABLET (ORAL)
- MEMANTINE TABLET (AG) (ORAL)
- MEMANTINE TABLET (ORAL)
- RIVASTIGMINE (AG) (TRANSDERM.)
- RIVASTIGMINE (TRANSDERM.)

Anthelmintics

Recommendations for the PDL are:

- ALBENDAZOLE (ORAL)
- EMVERM (ORAL)
- IVERMECTIN (ORAL)
- PRAZIQUANTEL (ORAL)

Anti-Allergens, Oral

Recommendations for the PDL are:

- None (all products in this class are recommended NPD)

Anticonvulsants

Recommendations for the PDL are:

- | | |
|--|---|
| • APTIOM (ORAL) | • LAMOTRIGINE DISPERSIBLE TABLET (ORAL) |
| • BANZEL SUSPENSION (ORAL) | • LAMOTRIGINE ODT (ORAL) |
| • BANZEL TABLET (ORAL) | • LAMOTRIGINE TABLET (ORAL) |
| • BRIVIACT SOLUTION (ORAL) | • LAMOTRIGINE XR (ORAL) |
| • BRIVIACT TABLET (ORAL) | • LEVETIRACETAM ER (ORAL) |
| • CARBAMAZEPINE CHEWABLE TABLET (ORAL) | • LEVETIRACETAM SOLUTION (ORAL) |
| • CARBAMAZEPINE TABLET (ORAL) | • LEVETIRACETAM TABLETS (ORAL) |
| • CARBATROL (ORAL) | • NAYZILAM (NASAL) |
| • CELONTIN (ORAL) | • OXCARBAZEPINE TABLETS (ORAL) |
| • CLOBAZAM SUSPENSION (ORAL) | • OXTELLAR XR (ORAL) |
| • CLOBAZAM TABLET (ORAL) | • PHENOBARBITAL ELIXIR (ORAL) |
| • CLONAZEPAM (ORAL) | • PHENOBARBITAL TABLET (ORAL) |

- CLONAZEPAM ODT (ORAL)
- DEPAKOTE SPRINKLE (ORAL)
- DIACOMIT CAPSULE (ORAL)
- DIACOMIT POWDER PACK (ORAL)
- DIASTAT (RECTAL)
- DIASTAT ACUDIAL (RECTAL)
- DIAZEPAM (AG) (RECTAL)
- DIAZEPAM DEVICE (AG) (RECTAL)
- DILANTIN 30 MG CAPSULE (ORAL)
- DIVALPROEX ER (ORAL)
- DIVALPROEX TABLET (ORAL)
- EPIDIOLEX (ORAL)
- ETHOSUXIMIDE CAPSULE (AG) (ORAL)
- ETHOSUXIMIDE CAPSULE (ORAL)
- ETHOSUXIMIDE SYRUP (ORAL)
- FELBAMATE SUSPENSION (ORAL)
- FELBAMATE TABLET (ORAL)
- FELBATOL TABLET (ORAL)
- FYCOMPA SUSPENSION (ORAL)
- FYCOMPA TABLET (ORAL)
- LACOSAMIDE SOLUTION (ORAL)
- LACOSAMIDE TABLET (ORAL)
- PHENYTOIN CAPSULE (ORAL)
- PHENYTOIN CHEWABLE TABLET (ORAL)
- PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL)
- PHENYTOIN SUSPENSION (AG) (ORAL)
- PHENYTOIN SUSPENSION (ORAL)
- PRIMIDONE (ORAL)
- SABRIL POWDER PACK (ORAL)
- SABRIL TABLET (ORAL)
- TEGRETOL XR (ORAL)
- TOPIRAMATE ER (QUDEXY) (AG) (ORAL)
- TOPIRAMATE SPRINKLE (ORAL)
- TOPIRAMATE TABLETS (ORAL)
- TRILEPTAL SUSPENSION (ORAL)
- TROKENDI XR (ORAL)
- VALPROIC ACID CAPSULE (ORAL)
- VALPROIC ACID SOLUTION (ORAL)
- VALTOCO (NASAL)
- XCOPRI TABLET (ORAL)
- XCOPRI TITRATION PAK (ORAL)
- ZONISAMIDE (ORAL)

Antidepressants, Other

Recommendations for the PDL are:

- BUPROPION (ORAL)
- BUPROPION SR (ORAL)
- BUPROPION XL (ORAL)
- MIRTAZAPINE ODT (ORAL)
- MIRTAZAPINE TABLET (ORAL)
- TRAZODONE (ORAL)
- VENLAFAXINE (ORAL)
- VENLAFAXINE ER CAPSULES (ORAL)

Antidepressants, SSRI

Recommendations for the PDL are:

- CITALOPRAM SOLUTION (ORAL)
- CITALOPRAM TABLET (ORAL)
- ESCITALOPRAM TABLET (ORAL)
- FLUOXETINE CAPSULE (ORAL)
- FLUOXETINE SOLUTION (ORAL)
- FLUVOXAMINE (ORAL)
- PAROXETINE TABLET (ORAL)
- SERTRALINE CONC (ORAL)
- SERTRALINE TABLET (ORAL)

Antihistamines, Minimally Sedating

Recommendations for the PDL are:

- CETIRIZINE SOLUTION (ORAL)
- CETIRIZINE SOLUTION OTC (ORAL)
- CETIRIZINE TABLETS OTC (ORAL)
- CETIRIZINE-D OTC (ORAL)
- LEVOCETIRIZINE TABLETS (ORAL)
- LEVOCETIRIZINE TABLETS OTC (ORAL)
- LORATADINE ODT OTC (ORAL)
- LORATADINE SOLUTION OTC (ORAL)
- LORATADINE TABLETS OTC (ORAL)
- LORATADINE-D OTC (ORAL)

Antihypertensives, Sympatholytics

Recommendations for the PDL are:

- CLONIDINE (ORAL)
- CLONIDINE (TRANSDERM)
- GUANFACINE (ORAL)
- METHYLDOPA (AG) (ORAL)
- METHYLDOPA (ORAL)

Antihyperuricemics

Recommendations for the PDL are:

- ALLOPURINOL (ORAL)
- COLCHICINE TABLET (AG) (ORAL)
- COLCHICINE TABLET (ORAL)
- FEBUXOSTAT (ORAL)
- PROBENECID (ORAL)

- PROBENECID / COLCHICINE (ORAL)

Antiparkinson's Agents

Recommendations for the PDL are:

- AMANTADINE CAPSULE (ORAL)
- AMANTADINE SYRUP (ORAL)
- BENZTROPINE (ORAL)
- CARBIDOPA / LEVODOPA (ORAL)
- CARBIDOPA / LEVODOPA ER (ORAL)
- CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL)
- PRAMIPEXOLE (ORAL)
- ROPINIROLE (ORAL)
- SELEGILINE TABLET (ORAL)
- TRIHEXYPHENIDYL ELIXIR (ORAL)
- TRIHEXYPHENIDYL TABLET (ORAL)

Antipsoriatics, Oral

Recommendations for the PDL are:

- ACITRETIN (AG) (ORAL)
- ACITRETIN (ORAL)

Antipsoriatics, Topical

Recommendations for the PDL are:

- CALCIPOTRIENE CREAM (TOPICAL)
- CALCIPOTRIENE SOLUTION (TOPICAL)

Antipsychotics

Recommendations for the PDL are:

- | | |
|---------------------------------------|----------------------------|
| • ABILIFY ASIMTUFII (INTRAMUSC) | • LATUDA (ORAL) |
| • ABILIFY MAINTENA (INTRAMUSC.) | • OLANZAPINE ODT (ORAL) |
| • AMITRIPTYLINE / PERPHENAZINE (ORAL) | • OLANZAPINE TABLET (ORAL) |
| • ARIPIRAZOLE TABLET (ORAL) | • PERPHENAZINE (ORAL) |
| • ARISTADA (INTRAMUSC) | • PERSERIS (SUBCUTANEOUS) |
| • ARISTADA INITIO (INTRAMUSC) | • PIMOZIDE (ORAL) |
| • CHLORPROMAZINE (ORAL) | • QUETIAPINE ER (ORAL) |

- CLOZAPINE (ORAL)
- FLUPHENAZINE DECANOATE (INJECTION)
- FLUPHENAZINE TABLET (ORAL)
- GEODON (INTRAMUSC)
- HALOPERIDOL (ORAL)
- HALOPERIDOL DECANOATE (INJECTION)
- HALOPERIDOL LACTATE (INJECTION)
- HALOPERIDOL LACTATE CONC (ORAL)
- INVEGA HAFYERA (INTRAMUSC)
- INVEGA SUSTENNA (INTRAMUSC)
- INVEGA TRINZA (INTRAMUSC)
- LOXAPINE (ORAL)
- LURASIDONE (ORAL)
- QUETIAPINE TABLETS (ORAL)
- RISPERDAL CONSTA (INTRAMUSC.)
- RISPERIDONE SOLUTION (ORAL)
- RISPERIDONE TABLET (ORAL)
- THIORIDAZINE (ORAL)
- THIOTHIXENE (ORAL)
- TRIFLUOPERAZINE (ORAL)
- UZEDY (SUBCUTANEOUS)
- VRAYLAR (ORAL)
- ZIPRASIDONE (INTRAMUSC)
- ZIPRASIDONE CAPSULE (AG) (ORAL)
- ZIPRASIDONE CAPSULE (ORAL)

Anxiolytics

Recommendations for the PDL are:

- ALPRAZOLAM TABLET (ORAL)
- BUSPIRONE (ORAL)
- LORAZEPAM TABLET (ORAL)

Bile Salts

Recommendations for the PDL are:

- URSODIOL TABLET (ORAL)
- URSODIOL 300 MG CAPSULE (ORAL)

Botulinum Toxins

Recommendations for the PDL are:

- BOTOX (INTRAMUSC)
- DYSPORT (INTRAMUSC)

Bronchodilators, Beta Agonist

Recommendations for the PDL are:

- ALBUTEROL HFA (PROAIR) (AG) (INHALATION)
- ALBUTEROL HFA (PROAIR) (INHALATION)
- ALBUTEROL HFA (PROVENTIL) (AG) (INHALATION)

- ALBUTEROL HFA (PROVENTIL) (INHALATION)
- ALBUTEROL NEB SOLN 0.63, 1.25 MG (AG) (INHALATION)
- ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)
- PROAIR HFA (INHALATION)
- PROVENTIL HFA (INHALATION)
- SEREVENT (INHALATION)
- VENTOLIN HFA (INHALATION)

Colony Stimulating Factors

Recommendations for the PDL are:

- FYLNETRA (SUBCUTANEOUS)
- NEUPOGEN DISP SYRIN (INJECTION)
- NEUPOGEN VIAL (INJECTION)

COPD Agents

Recommendations for the PDL are:

- ANORO ELLIPTA (INHALATION)
- ATROVENT HFA (INHALATION)
- COMBIVENT RESPIMAT (INHALATION)
- IPRATROPIUM / ALBUTEROL (INHALATION)
- IPRATROPIUM NEBULIZER (INHALATION)
- ROFLUMILAST (ORAL)
- SPIRIVA (INHALATION)
- STIOLTO RESPIMAT (INHALATION)

Cytokine and CAM Antagonists

Recommendations for the PDL are:

- ENBREL MINI CARTRIDGE (SUBCUTANE.)
- ENBREL PEN (INJECTION)
- ENBREL SYRINGE (INJECTION)
- ENBREL VIAL (SUBCUTANEOUS)
- HUMIRA KIT (INJECTION) (CF) 100 MG/ML
- HUMIRA KIT (INJECTION) 50 MG/ML
- HUMIRA PEN KIT (INJECTION) (CF) 100 MG/ML
- HUMIRA PEN KIT (INJECTION) 50 MG/ML
- INFliximab (INJECTION)
- OTEZLA (ORAL)
- XELJANZ (ORAL)

Emollients

Recommendations for the PDL are:

- AMMONIUM LACTATE CREAM/LOTION (TOPICAL)

Enzyme Replacement, Gaucher Disease

Recommendations for the PDL are:

- None (all products in this class are recommended NPD)

Epinephrine, Self-Injected

Recommendations for the PDL are:

- AUVI-Q 0.1 MG (INTRAMUSC)
- EPINEPHRINE 0.15 MG (EPIPEN JR) (AG) (INJECTION)
- EPINEPHRINE 0.15 MG (EPIPEN JR) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (AG) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (INJECTION)
- EPIPEN (INTRAMUSC)
- EPIPEN JR (INTRAMUSC)

Erythropoiesis Stimulating Proteins

Recommendations for the PDL are:

- ARANESP DISP SYRIN (INJECTION)
- ARANESP VIAL (INJECTION)
- EPOGEN (INJECTION)
- RETACRIT (INJECTION)

Glucocorticoids, Inhaled

Recommendations for the PDL are:

- ADVAIR DISKUS (INHALATION)
- ADVAIR HFA (INHALATION)
- ARNUITY ELLIPTA (INHALATION)
- ASMANEX (INHALATION)
- BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)
- BUDESONIDE 1 MG RESPULES (INHALATION)
- DULERA (INHALATION)
- FLOVENT HFA (INHALATION)
- FLUTICASONE HFA (AG) (INHALATION)
- SYMBICORT (INHALATION)
- TRELEGY ELLIPTA (INHALATION)

Glucocorticoids, Oral

Recommendations for the PDL are:

- BUDESONIDE EC (ORAL)
- DEXAMETHASONE TABLET (ORAL)
- HYDROCORTISONE (ORAL)
- METHYLPREDNISOLONE TAB DS PK (ORAL)
- PREDNISOLONE SODIUM PHOSPHATE (ORAL)
- PREDNISOLONE SOLUTION (ORAL)
- PREDNISONE TABLET (ORAL)

Hemophilia Treatment

Recommendations for the PDL are:

- ALPHANATE (INTRAVEN.)
- BENEFIX KIT (INTRAVEN.)
- COAGADEX (INTRAVEN)
- CORIFACT KIT (INTRAVEN)
- HEMLIBRA (SUBCUTANE.)
- HUMATE-P KIT (INTRAVEN.)
- JIVI (INTRAVEN)
- KOVALTRY (INTRAVEN.)
- NOVOEIGHT (INTRAVEN)
- NOVOSEVEN RT (INTRAVEN)
- NUWIQ (INTRAVEN)
- REBINYN (INTRAVEN)
- WILATE (INTRAVEN)
- XYNTHA KIT (INTRAVEN)
- XYNTHA SOLOFUSE SYRINGE KIT (INTRAVEN.)

Histamine II Receptor Blockers

Recommendations for the PDL are:

- FAMOTIDINE SUSPENSION (ORAL)
- FAMOTIDINE TABLET (ORAL)

Idiopathic Pulmonary Fibrosis

Recommendations for the PDL are:

- OFEV (ORAL)
- PIRFENIDONE CAPSULE (ESBRIET) (ORAL)
- PIRFENIDONE TABLET (ESBRIET) (ORAL)

Immune Globulins

Recommendations for the PDL are:

- GAMMAGARD LIQUID (INJECTION)
- GAMUNEX-C (INJECTION)
- HIZENTRA SYRINGE (SUBCUTANEOUS)
- HIZENTRA VIAL (SUBCUTANEOUS)
- PRIVIGEN (INTRAVEN)

Immunomodulators, Asthma

Recommendations for the PDL are:

- FASENRA PEN (SUBCUTANEOUS)
- FASENRA SYRINGE (SUBCUTANEOUS)
- XOLAIR SYRINGE (SUB-Q)
- XOLAIR VIAL (SUB-Q)

Immunomodulators, Atopic Dermatitis

Recommendations for the PDL are:

- ADBRY (SUBCUTANEOUS)
- DUPIXENT PEN (SUBCUTANEOUS)
- DUPIXENT SYRINGE (SUBCUTANEOUS)
- ELIDEL (TOPICAL)
- EUCRISA (TOPICAL)

Immunomodulators, Lupus

Recommendations for the PDL are:

- None (all products in this class are recommended NPD)

Immunomodulators, Topical

Recommendations for the PDL are:

- CONDYLOX GEL (TOPICAL)
- IMIQUIMOD (ALDARA) (TOPICAL)

Immunosuppressives, Oral

Recommendations for the PDL are:

- SIROLIMUS SOLUTION (ORAL) – from NPD to preferred
- SIROLIMUS TABLET (ORAL) – from NPD to preferred

Intranasal Rhinitis Agents

Recommendations for the PDL are:

- AZELASTINE (ASTELIN) (NASAL)
- AZELASTINE (ASTEPRO) (AG) (NASAL)
- AZELASTINE (ASTEPRO) (NASAL)
- FLUTICASONE (NASAL)
- IPRATROPIUM (NASAL)

Leukotriene Modifiers

Recommendations for the PDL are:

- MONTELUKAST CHEWABLE TABLET (ORAL)
- MONTELUKAST TABLET (ORAL)

Methotrexate

Recommendations for the PDL are:

- METHOTREXATE PF VIAL (AG) (INJECTION)
- METHOTREXATE PF VIAL (INJECTION)
- METHOTREXATE TABLET (ORAL)
- METHOTREXATE VIAL (INJECTION)

Movement Disorders

Recommendations for the PDL are:

- AUSTEDO (ORAL)
- AUSTEDO XR (ORAL)
- AUSTEDO XR TITR PK (ORAL)
- INGREZZA (ORAL)
- INGREZZA INITIATION PACK (ORAL)
- TETRABENAZINE (ORAL)

Neuropathic Pain

Recommendations for the PDL are:

- DULOXETINE (CYMBALTA) (ORAL)
- GABAPENTIN CAPSULE (ORAL)
- GABAPENTIN SOLUTION (AG) (ORAL)
- GABAPENTIN SOLUTION (ORAL)

- GABAPENTIN TABLET (ORAL)
- LIDOCAINE (AG) (TOPICAL)
- LIDOCAINE (TOPICAL)
- LIDODERM (TOPICAL)
- PREGABALIN CAPSULE (AG) (ORAL)
- PREGABALIN CAPSULE (ORAL)
- PREGABALIN SOLUTION (AG) (ORAL)
- PREGABALIN SOLUTION (ORAL)
- SAVELLA (ORAL)
- SAVELLA DOSE PACK (ORAL)
- ZTLIDO (TOPICAL)

NSAIDS

Recommendations for the PDL are:

- | | |
|-------------------------------|-----------------------------------|
| • CELECOXIB (AG) (ORAL) | • KETOROLAC (ORAL) |
| • CELECOXIB (ORAL) | • MELOXICAM TABLET (ORAL) |
| • DICLOFENAC GEL (TOPICAL) | • NABUMETONE (ORAL) |
| • DICLOFENAC SODIUM (ORAL) | • NAPROXEN SUSPENSION (AG) (ORAL) |
| • IBUPROFEN SUSPENSION (ORAL) | • NAPROXEN SUSPENSION (ORAL) |
| • IBUPROFEN TABLET (ORAL) | • NAPROXEN TABLET (ORAL) |
| • INDOMETHACIN CAPSULE (ORAL) | • SULINDAC (ORAL) |

Oncology, Oral – Breast

Recommendations for the PDL are:

- ANASTROZOLE (ORAL)
- CAPECITABINE (ORAL)
- CYCLOPHOSPHAMIDE (ORAL)
- EXEMESTANE (ORAL)
- FULVESTRANT (AG) (INTRAMUSC)
- FULVESTRANT (INTRAMUSC)
- IBRANCE CAPSULE (ORAL)
- IBRANCE TABLET (ORAL)
- LETROZOLE (ORAL)
- TAMOXIFEN CITRATE (ORAL)

Oncology, Oral - Hematologic

Recommendations for the PDL are:

- HYDROXYUREA (ORAL)
- IMATINIB (ORAL)
- IMBRUVICA CAPSULE (ORAL)
- IMBRUVICA TABLET (ORAL)
- JAKAFI (ORAL)
- LEUKERAN (ORAL)
- MATULANE (ORAL)
- MELPHALAN (ORAL)
- MERCAPTOPURINE (ORAL)
- MYLERAN (ORAL)
- REVLIMID (ORAL)
- SPRYCEL (ORAL)
- TRETINOIN (ORAL)
- VENCLEXTA (ORAL)
- VENCLEXTA STARTING PACK (ORAL)

Oncology, Oral – Lung

Recommendations for the PDL are:

- ALECENSA (ORAL)
- GILOTRIF (ORAL)
- HYCAMTIN (ORAL)
- TAGRISSO (ORAL)
- XALKORI (ORAL)

Oncology, Oral – Other

Recommendations for the PDL are:

- KOSELUGO (ORAL)
- TEMOZOLOMIDE (ORAL)
- ZEJULA (ORAL)

Oncology, Oral – Prostate

Recommendations for the PDL are:

- ABIRATERONE (ORAL)
- BICALUTAMIDE (ORAL)
- FLUTAMIDE (ORAL)
- XTANDI CAPSULE (ORAL)
- XTANDI TABLET (ORAL)

Oncology, Oral - Renal Cell

Recommendations for the PDL are:

- EVEROLIMUS TABLET (AFINITOR) (ORAL)
- INLYTA (ORAL)

- LENVIMA (ORAL)
- NEXAVAR (ORAL)
- SORAFENIB (ORAL)
- SUNITINIB (ORAL)
- SUTENT (ORAL)
- VOTRIENT (ORAL)

Oncology, Oral – Skin

Recommendations for the PDL are:

- COTELLIC (ORAL)
- MEKINIST (ORAL)
- ODOMZO (ORAL)
- TAFINLAR (ORAL)
- ZELBORAF (ORAL)

Ophthalmic Antibiotic/Steroid Combinations

Recommendations for the PDL are:

- NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)
- SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)
- TOBRADEX OINTMENT (OPHTHALMIC)
- TOBRADEX SUSPENSION (OPHTHALMIC)
- TOBRAMYCIN / DEXAMETHASONE SUSPENSION (AG) (OPHTHALMIC)
- TOBRAMYCIN / DEXAMETHASONE SUSPENSION (OPHTHALMIC)

Ophthalmic Antibiotics

Recommendations for the PDL are:

- | | |
|---|--|
| • BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC) | • MOXIFLOXACIN (VIGAMOX) (OPHTHALMIC) |
| • CIPROFLOXACIN SOLUTION (OPHTHALMIC) | • NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC) |
| • ERYTHROMYCIN (OPHTHALMIC) | • OFLOXACIN (OPHTHALMIC) |
| • GENTAMICIN DROPS (OPHTHALMIC) | • POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC) |
| • MOXIFLOXACIN (AG) (VIGAMOX) (OPHTHALMIC) | • SULFACETAMIDE SOLUTION (OPHTHALMIC) |
| | • TOBRAMYCIN DROPS (OPHTHALMIC) |

Ophthalmics for Allergic Conjunctivitis

Recommendations for the PDL are:

- ALREX (OPHTHALMIC)
- AZELASTINE (OPHTHALMIC)
- CROMOLYN SODIUM (OPHTHALMIC)
- OLOPATADINE (PATANOL) (OPHTHALMIC)

Ophthalmic Anti-inflammatories

Recommendations for the PDL are:

- DEXAMETHASONE (OPHTHALMIC)
- DICLOFENAC (OPHTHALMIC)
- DIFLUPREDNATE (AG) (OPHTHALMIC)
- DIFLUPREDNATE (OPHTHALMIC)
- DUREZOL (OPHTHALMIC)
- FLUOROMETHOLONE (OPHTHALMIC)
- FLURBIPROFEN (OPHTHALMIC)
- KETOROLAC (OPHTHALMIC)
- KETOROLAC LS (OPHTHALMIC)
- PREDNISOLONE ACETATE (OPHTHALMIC)

Ophthalmics, Anti-Inflammatory/Immunomodulator

Recommendations for the PDL are:

- RESTASIS (OPHTHALMIC)
- RESTASIS MULTIDOSE (OPHTHALMIC)
- XIIDRA (OPHTHALMIC)

OPHTHALMICS, CYSTINOSIS

Recommendations for the PDL are:

- None (all products in this class are recommended NPD)

Ophthalmics, Glaucoma Agents

Recommendations for the PDL are:

- | | |
|--------------------------------------|---------------------------------------|
| • ALPHAGAN P 0.15% (OPHTHALMIC) | • ROCKLATAN (OPHTHALMIC) |
| • BRIMONIDINE 0.2% (OPHTHALMIC) | • SIMBRINZA (OPHTHALMIC) |
| • CARTEOLOL (OPHTHALMIC) | • TIMOLOL (OPHTHALMIC) |
| • COMBIGAN (OPHTHALMIC) | • TRAVATAN Z 2.5 ML (OPHTHALMIC) |
| • DORZOLAMIDE (OPHTHALMIC) | • TRAVATAN Z 5 ML (OPHTHALMIC) |
| • DORZOLAMIDE / TIMOLOL (OPHTHALMIC) | • TRAVOPROST 2.5 ML (AG) (OPHTHALMIC) |
| • LATANOPROST 2.5 ML (OPHTHALMIC) | • TRAVOPROST 2.5 ML (OPHTHALMIC) |

- LEVOBUNOLOL (OPHTHALMIC)
- RHOPRESSA (OPHTHALMIC)
- TRAVOPROST 5 ML (AG) (OPHTHALMIC)
- TRAVOPROST 5 ML (OPHTHALMIC)

Otic Anti-infectives & Anesthetics

Recommendations for the PDL are:

- ACETIC ACID (OTIC)
- ACETIC ACID HC (OTIC)

Otic Antibiotics

Recommendations for the PDL are:

- CIPRODEX (OTIC)
- CIPROFLOXACIN/DEXAMETHASONE (AG) (OTIC)
- CIPROFLOXACIN/DEXAMETHASONE (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (AG) (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)
- OFLOXACIN (OTIC)

Progestational Agents

Recommendations for the PDL are:

- MEDROXYPROGESTERONE ACETATE (AG) (ORAL)
- MEDROXYPROGESTERONE ACETATE (ORAL)
- NORETHINDRONE ACETATE (ORAL)
- PROGESTERONE CAPSULE (ORAL)

Sedative Hypnotics

Recommendations for the PDL are:

- TEMAZEPAM (AG) (ORAL)
- TEMAZEPAM (ORAL)
- TRIAZOLAM (ORAL)
- ZOLPIDEM (ORAL)
- ZOLPIDEM ER (ORAL)

Sickle Cell Anemia Treatments

Recommendations for the PDL are:

- DROXIA (ORAL)

Smoking Cessation

Recommendations for the PDL are:

- BUPROPION SR (ORAL)
- CHANTIX (ORAL)
- CHANTIX DOSE PACK (ORAL)
- NICOTINE GUM OTC (BUCCAL)
- NICOTINE LOZENGE OTC (BUCCAL)
- NICOTINE PATCH OTC (TRANSDERMAL)
- VARENICLINE DOSE PACK (ORAL)
- VARENICLINE TARTRATE (ORAL)

Spinal Muscular Atrophy – New

Recommendations for the PDL are:

- None (all products in this class are recommended NPD)

Steroids Topical, High

Recommendations for the PDL are:

- BETAMET DIPROP / PROP GLY CREAM (TOPICAL)
- BETAMETHASONE VALERATE CREAM (TOPICAL)
- BETAMETHASONE VALERATE LOTION (TOPICAL)
- BETAMETHASONE VALERATE OINTMENT (TOPICAL)
- TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)
- TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)
- TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)

Steroids Topical, Low

Recommendations for the PDL are:

- HYDROCORTISONE CREAM (RECTAL)
- HYDROCORTISONE CREAM (TOPICAL)
- HYDROCORTISONE LOTION (TOPICAL)
- HYDROCORTISONE OINTMENT (TOPICAL)

Steroids Topical, Medium .

Recommendations for the PDL are:

- FLUTICASONE PROPIONATE CREAM (TOPICAL)
- FLUTICASONE PROPIONATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE CREAM (TOPICAL)
- MOMETASONE FUROATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE SOLUTION (TOPICAL)

Steroids Topical, Very High

Recommendations for the PDL are:

- CLOBETASOL EMOLLIENT (TOPICAL)
- CLOBETASOL PROPIONATE CREAM (TOPICAL)
- CLOBETASOL PROPIONATE GEL (TOPICAL)
- CLOBETASOL PROPIONATE OINTMENT (TOPICAL)
- CLOBETASOL PROPIONATE SOLUTION (TOPICAL)
- HALOBETASOL PROPIONATE CREAM (TOPICAL)
- HALOBETASOL PROPIONATE OINTMENT (TOPICAL)

Stimulants and Related Agents

Recommendations for the PDL are:

- | | |
|---|---|
| • ADDERALL XR (ORAL) | • METHYLPHENIDATE CD (AG) (ORAL) |
| • AMPHETAMINE SALT COMBO (ORAL) | • METHYLPHENIDATE CD (ORAL) |
| • ATOMOXETINE (ORAL) | • METHYLPHENIDATE ER (CONCERTA) (AG) (ORAL) |
| • DEXMETHYLPHENIDATE (ORAL) | • METHYLPHENIDATE ER (CONCERTA) (ORAL) |
| • DEXMETHYLPHENIDATE ER (ORAL) | • METHYLPHENIDATE ER (RITALIN LA) (ORAL) |
| • DEXTROAMPHETAMINE TABLET (ORAL) | • METHYLPHENIDATE SOLUTION (ORAL) |
| • GUANFACINE ER (ORAL) | • MODAFINIL (ORAL) |
| • LISDEXAMFETAMINE CAPSULE (ORAL) | • QUILLICHEW ER (ORAL) |
| • LISDEXAMFETAMINE CHEWABLE TABLET (ORAL) | • QUILLIVANT XR (ORAL) |
| • METHYLPHENIDATE (ORAL) | • VYVANSE CAPSULE (ORAL) |
| | • VYVANSE CHEWABLE TABLET (ORAL) |

Thrombopoiesis Stimulating Proteins

Recommendations for the PDL are:

- PROMACTA TABLET (ORAL)

Urea Cycle Disorders, Oral – New

Recommendations for the PDL are:

- PHEBURANE (ORAL)

Single Drug Reviews

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing	Drug/Issue
John Landis	Braeburn	Brixadi
**NOTE: Names of speakers who were present and yielded their time back were not captured.		

Acne Agents, Topical

- ZMA CLEAR CLEANSER (TOPICAL) – recommended NPD

Antibiotics, GI

- VOWST CAPSULE (ORAL) - recommended NPD

Antimigraine Agents, Other

- ZAVZPRET (NASAL) - recommended NPD

Cystic Fibrosis, Oral

- TRIKAFTA PACKET (ORAL) – recommended NPD

Growth Hormone

- SOGROYA (SUBCUTANEOUS) – recommended preferred

Hypoglycemics, Insulin and Related Agents

- REZVOGLAR KWIKPEN (SUBCUTANEOUS) – recommended NPD

Hypoglycemics, SGLT2

- INPEFA (ORAL) - recommended NPD

Lipotropics, Statins

- ATORVALIQ (ORAL) - recommended NPD

Multiple Sclerosis

- BRIUMVI (INTRAVEN.) - recommended NPD

Opiate Dependence Treatments

- BRIXADI MONTHLY (SUBCUTANEOUS) - recommended NPD
- BRIXADI WEEKLY (SUBCUTANEOUS) - recommended NPD

PAH Agents, Oral and Inhaled

- LIQREV SUSPENSION (ORAL) - recommended NPD

Other Business

Dr. Wendt announced that Magellan will be single PBM vendor starting tomorrow. Magellan will handle POS, PAs, and other PBM matters for MCOs; FFS PBM will continue to be handled by Gainwell.

Dr. Hussey announced that this meeting may be his last one because he is trying to retire in January 2024. Dr. Wendt and Mr. Orlando thanked him for his service.

Next Steps

- A. Proposed Therapeutic Classes to be Reviewed at Next Meeting.** Dr. Douiki presented the list of therapeutic classes to be reviewed at the spring 2024 P&T meeting.
- B. Next Meeting Date.** The next committee meeting is tentatively scheduled for April 26, 2024.
- C. Public Testimony.** None.

Adjournment

Mr. Orlando made the motion to adjourn. Dr. Hussey seconded the motion. The meeting adjourned at or about 11:10 a.m.

By Orlando
10/30/24